Advanced Search

Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2016 August;64(4) > Minerva Cardioangiologica 2016 August;64(4):462-72

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752

 

Minerva Cardioangiologica 2016 August;64(4):462-72

NEW BIORESORBABLE TECHNOLOGY IN INTERVENTIONAL CARDIOLOGY 

 REVIEWS

Long-term results of BVS implantation: a focus on safety and efficacy of the bioresorbable technology

Wijnand K. DEN DEKKER, Robert J. VAN GEUNS, Roberto DILETTI

Department of Interventional Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands

The everolimus eluting bioresorbable vascular scaffold (BVS) represents a novel technology and a novel paradigm for treatment of coronary artery disease, with the potential of improving the long-term clinical outcomes after complete bioresorption. The increasing amount of clinical data is adding in a gradual understanding of the appropriate implantation technique, but long-term results after BVS implantation are sparse. In addition, concern related to a possible increased rate of scaffold thrombosis has recently risen. The present article reviews the current status of knowledge on bioresorbable vascular scaffold from the preclinical phase and the first-in-man experience to the recently reported large randomized trials. Challenging subsets are discussed as well as possible factors impacting on the occurrence of thrombotic events, particularly focusing on clinical outcomes reported in the longest follow-ups currently available.

language: English


FULL TEXT  REPRINTS

top of page